The dynamics of HER2-low expression during breast cancer progression

ConclusionsHER2-low BCs constitute a heterogeneous group of tumors. Low HER2 expression is dynamic, with significant discordance between primary tumors and advanced disease as well as the distant sites of relapse. Repeat biomarker studies from advanced disease are warranted in making appropriate treatment plans in the pursuit of precision medicine.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research